Cancer Res Treat.  2021 Jul;53(3):874-880. 10.4143/crt.2020.1066.

Clinical Experience of Male Primary Choriocarcinoma at the Samsung Medical Center

• Ji YS
• Park SH

• KMID: 2518411
• DOI: http://doi.org/10.4143/crt.2020.1066

Abstract

Purpose
The objective of this study was to describe and analyze the clinicopathological features of primary choriocarcinoma (PCC) observed in male patients treated at the Samsung Medical Center between 1996 and 2020.
Materials and Methods
We reviewed the clinical records of 14 male patients with PCC retrospectively to assess their demographic, histological, and clinical characteristics at the time of diagnosis as well as identify the treatment outcomes.
Results
The median age of the patients was 33 years. The primary tumor site was the testicles in seven cases (50%), the mediastinum in six cases (43%), and the brain in one case (7%). The most common metastatic site was the lungs (79%), followed by the brain (43%). All patients with PCC received cytotoxic chemotherapy. Twelve patients had records of their response to cytotoxic chemotherapy; of these 12 patients, eight (8/12, 67%) achieved an objective response, and four (4/12, 33%) achieved stable disease response as the best response during chemotherapy.
Conclusion
It is known that most male PCC patients eventually develop resistance to cytotoxic chemotherapy and die. Factors such as poor response to chemotherapy, high disease burden, brain metastasis, and hemoptysis at the time of diagnosis are associated with shorter survival time in male PCC patients. Programmed death-1/programmed death-ligand 1 blockade therapy can be a salvage treatment for chemotherapy-resistant male PCC patients.

Keyword

Primary choriocarcinoma; Male choriocarcinoma; Choriocarcinoma; Immune checkpoint inhibitors; Anti-PD-1 antibodies; PD-L1

Reference

References

1. Siddiqui BA, Zhang M, Pisters LL, Tu SM. Systemic therapy for primary and extragonadal germ cell tumors: prognosis and nuances of treatment. Transl Androl Urol. 2020; 9(Suppl 1):S56–65.

2. Chahoud J, Kohli M. Managing extragonadal germ cell tumors in male adults. AME Med J. 2020; 5:8.

3. Shen H, Shih J, Hollern DP, Wang L, Bowlby R, Tickoo SK, et al. Integrated molecular characterization of testicular germ cell tumors. Cell Rep. 2018; 23:3392–406.

4. Rejlekova K, Cursano MC, De Giorgi U, Mego M. Severe complications in testicular germ cell tumors: the choriocarcinoma syndrome. Front Endocrinol (Lausanne). 2019; 10:218.

5. Stockton L, Green E, Kaur B, De Winton E. Non-gestational choriocarcinoma with widespread metastases presenting with type 1 respiratory failure in a 39-year-old female: case report and review of the literature. Case Rep Oncol. 2018; 11:151–8.

6. Garrett A, Knehans A, Phaeton R, Kesterson JP. Pure nongestational ovarian choriocarcinoma: a scoping review. Integr Cancer Sci Ther. 2017; 4:1–8.

7. Jiang F, Xiang Y, Feng FZ, Ren T, Cui ZM, Wan XR. Clinical analysis of 13 males with primary choriocarcinoma and review of the literature. Onco Targets Ther. 2014; 7:1135–41.

8. Reilley MJ, Pagliaro LC. Testicular choriocarcinoma: a rare variant that requires a unique treatment approach. Curr Oncol Rep. 2015; 17:2.

9. Darvin P, Toor SM, Sasidharan Nair V, Elkord E. Immune checkpoint inhibitors: recent progress and potential biomarkers. Exp Mol Med. 2018; 50:1–11.

10. Veras E, Kurman RJ, Wang TL, Shih IM. PD-L1 expression in human placentas and gestational trophoblastic diseases. Int J Gynecol Pathol. 2017; 36:146–53.

11. Ghorani E, Kaur B, Fisher RA, Short D, Joneborg U, Carlson JW, et al. Pembrolizumab is effective for drug-resistant gestational trophoblastic neoplasia. Lancet. 2017; 390:2343–5.

12. Goldfarb JA, Dinoi G, Mariani A, Langstraat CL. A case of multi-agent drug resistant choriocarcinoma treated with pembrolizumab. Gynecol Oncol Rep. 2020; 32:100574.

13. Huang M, Pinto A, Castillo RP, Slomovitz BM. Complete serologic response to pembrolizumab in a woman with chemoresistant metastatic choriocarcinoma. J Clin Oncol. 2017; 35:3172–4.

14. Chi EA, Schweizer MT. Durable response to immune checkpoint blockade in a platinum-refractory patient with nonseminomatous germ cell tumor. Clin Genitourin Cancer. 2017; 15:e855–7.

15. Loh KP, Fung C. Novel therapies in platinum-refractory metastatic germ cell tumor: a case report with a focus on a PD-1 inhibitor. Rare Tumors. 2017; 9:6867.

16. Han C, Zhou Y, Ma JA, Liu J, Jiang YN, Zhang HX. A promising treatment option for refractory male primary choriocarcinoma: report of two cases. Transl Cancer Res. 2020; 9:3054–60.

17. Adra N, Einhorn LH, Althouse SK, Ammakkanavar NR, Musapatika D, Albany C, et al. Phase II trial of pembrolizumab in patients with platinum refractory germ-cell tumors: a Hoosier Cancer Research Network Study GU14–206. Ann Oncol. 2018; 29:209–14.